Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicorandil and ranolazine for prevention of contrast-induced nephropathy in elective angioplasty
IRCT20120215009014N592Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of nicorandil and ranolazine in contrast-induced nephropathy (CIN) and acute kidney failure (AKF) (3 arms), sponsored by Hamadan University of Medical Sciences. Started Jan 2026; status: completed.
02
Drugs
nicorandilranolazine
03
Conditions
contrast-induced nephropathy (CIN)acute kidney failure (AKF)
Beyond the preview
Go deeper on IRCT20120215009014N592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120215009014N592.